NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director James N. Topper bought 1,260 shares of the business's stock in a transaction dated Wednesday, June 25th. The stock was bought at an average price of $18.26 per share, for a total transaction of $23,007.60. Following the purchase, the director now owns 3,026,133 shares in the company, valued at approximately $55,257,188.58. This represents a 0.04% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
NewAmsterdam Pharma Trading Up 0.7%
Shares of NASDAQ NAMS traded up $0.12 during mid-day trading on Thursday, hitting $18.45. The company had a trading volume of 755,738 shares, compared to its average volume of 707,775. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $27.29. The firm's 50 day simple moving average is $18.64 and its two-hundred day simple moving average is $20.80.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. The company had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million. Equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the company. Wall Street Zen lowered NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a report on Saturday, June 21st. Stifel Nicolaus started coverage on NewAmsterdam Pharma in a research report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 target price for the company. Citigroup began coverage on NewAmsterdam Pharma in a report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 price target for the company. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research report on Monday, March 3rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $42.89.
Read Our Latest Stock Analysis on NAMS
Institutional Trading of NewAmsterdam Pharma
A number of large investors have recently modified their holdings of NAMS. Quarry LP acquired a new position in NewAmsterdam Pharma during the 1st quarter valued at about $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $50,000. National Bank of Canada FI acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of NewAmsterdam Pharma by 19.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after buying an additional 596 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of NewAmsterdam Pharma by 130.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after buying an additional 3,390 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NewAmsterdam Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.
While NewAmsterdam Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
